PTD DBM.

PTD DBM is a research compound in the copper & cosmetic peptides.

Its biological effect is described in the mechanism section.

It draws interest for copper & cosmetic peptides.

F-tier evidence: no meaningful human evidence; support is preclinical or mechanistic.

What it is

PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy. It was created as a research tool to manipulate Wnt/β-catenin signaling in skin and hair-follicle biology and is not a drug, nutritional product, or approved therapeutic.

How it works

CXXC-type zinc finger protein 5 (CXXC5) is a negative-feedback regulator of canonical Wnt/β-catenin signaling that works by binding the scaffolding protein Dishevelled (Dvl), preventing Dvl from transmitting the Wnt signal. PTD-DBM carries a sequence that imitates the Dvl-binding motif, so it competitively occupies that interface and disrupts the CXXC5–Dvl interaction. Freed from CXXC5 inhibition, Dvl can stabilize β-catenin, which in turn drives transcriptional programs associated with the anagen (growth) phase of the hair cycle, dermal-papilla activity, and epithelial proliferation in wounds. In the founding work this de-repression of Wnt signaling was the proposed basis for both accelerated hair regrowth and wound-induced hair neogenesis (de novo follicle formation within healing skin).

What the evidence shows

The evidence base is preclinical. The foundational study (Lee et al., J Invest Dermatol 2017, PMID 28595998) reported that CXXC5 is elevated in balding human scalp and that disrupting the CXXC5–Dishevelled interaction with the competing peptide activated Wnt/β-catenin signaling, accelerated hair regrowth, and promoted wound-induced hair neogenesis in mice; effects were enhanced when combined with valproic acid (a GSK3β-modulating Wnt activator), and Cxxc5-knockout mice phenocopied the benefit. Earlier work established CXXC5 itself as a negative regulator of cutaneous wound healing (Lee et al., J Exp Med 2015, PMID 26056233), and a 2023 study (Cells, PMID 36831222) linked CXXC5 to DHT/PGD2-driven androgenetic alopecia, supporting the target's relevance. The same Yonsei group later advanced a small-molecule Wnt activator, KY19382 (Br J Pharmacol 2021, PMID 33751552), as a more drug-like successor. Critically, no human clinical trials of PTD-DBM have been published; human relevance rests on cultured human follicle cells and on the observation of elevated CXXC5 in bald scalp, not on controlled efficacy data in people.

Safety considerations

There are no published human safety data, pharmacokinetics, or toxicology studies for PTD-DBM; it has been used only as an experimental reagent in animal and cell-culture models, so its safety profile in humans is genuinely unknown. As a cell-penetrating peptide that broadly de-represses Wnt/β-catenin signaling, a theoretical concern is that sustained or systemic Wnt activation could have off-target effects on tissues where the pathway influences proliferation, though no such outcomes have been characterized for this peptide specifically. Material sold online is research-use-only, is not produced or tested to pharmaceutical quality standards, and purity, sterility, and identity cannot be assumed. Anyone encountering PTD-DBM should treat it strictly as an unapproved experimental compound.

Regulatory status

PTD-DBM is an investigational research compound; it is not approved by the FDA or any major regulator for any indication, and it is not in marketed dermatologic products. It is not a WADA-listed substance, and the published work remains preclinical with no registered human clinical program for the peptide itself.

1. [1]Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis — Journal of Investigative Dermatology, 2017, 137(11):2260-2269, PMID 28595998
2. [2]The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing — Journal of Experimental Medicine, 2015, PMID 26056233
3. [3]CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2 — Cells, 2023, 12(4):555, PMID 36831222
4. [4]KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis — British Journal of Pharmacology, 2021, 178(12):2533-2546, PMID 33751552

• Not FDA-approved; research-only.
• Human hair-regrowth evidence is minimal.

Stack fit

Why not D: held back by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• PTD DBM is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Copper & cosmetic peptides class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The early-evidence lane
3. Why Minimal, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently